Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08PMW
|
|||
| Former ID |
DIB009901
|
|||
| Drug Name |
BMS-223131
|
|||
| Synonyms |
4-(5-Chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)quinolin-2(1H)-one
Click to Show/Hide
|
|||
| Indication | Erectile dysfunction [ICD-11: HA01.1; ICD-10: N48.4; ICD-9: 302.72, 607.84] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H13ClF3NO3
|
|||
| Canonical SMILES |
C1=CC2=C(C=C1C(F)(F)F)C(=C(C(=O)N2)CCO)C3=C(C=CC(=C3)Cl)O
|
|||
| InChI |
1S/C18H13ClF3NO3/c19-10-2-4-15(25)13(8-10)16-11(5-6-24)17(26)23-14-3-1-9(7-12(14)16)18(20,21)22/h1-4,7-8,24-25H,5-6H2,(H,23,26)
|
|||
| InChIKey |
QESHSZWKJULSAR-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 275375-69-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Charybdotoxin receptor beta-4 (BKbeta4) | Target Info | Modulator | [1] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Vascular smooth muscle contraction | ||||
| Insulin secretion | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| Reactome | cGMP effects | |||
| WikiPathways | Potassium Channels | |||
| Platelet homeostasis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance ... J Pharmacol Exp Ther. 2005 May;313(2):840-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.